Paul S. Meltzer
YOU?
Author Swipe
View article: Protocol to set up the CellMinerCDB pharmacogenomics analysis web application with custom cell line data
Protocol to set up the CellMinerCDB pharmacogenomics analysis web application with custom cell line data Open
View article: Azanucleoside treatment leads to B-cell precursor acute lymphoblastic leukemia
Azanucleoside treatment leads to B-cell precursor acute lymphoblastic leukemia Open
View article: Disruption of normal stem cell function and transmission of myelodysplastic syndrome by self-renewal of committed myeloid lineage cells
Disruption of normal stem cell function and transmission of myelodysplastic syndrome by self-renewal of committed myeloid lineage cells Open
View article: 194 | A NOVEL APPROACH FOR CLASSIFICATION OF SPLENIC B CELL LYMPHOMA USING DNA METHYLATION REVEALS DIVERSE BIOLOGICAL DISEASE MECHANISMS
194 | A NOVEL APPROACH FOR CLASSIFICATION OF SPLENIC B CELL LYMPHOMA USING DNA METHYLATION REVEALS DIVERSE BIOLOGICAL DISEASE MECHANISMS Open
View article: Cancer-associated DAXX mutations reveal a critical role for ATRX localization in ALT suppression
Cancer-associated DAXX mutations reveal a critical role for ATRX localization in ALT suppression Open
To maintain genome stability, proliferating cells must enact a program of telomere maintenance. While most tumors maintain telomeres through the action of telomerase, a subset of tumors utilize a DNA-templated process termed Alternative Le…
View article: Supp_Tables_S1-S13 from The DNA Methyltransferase Inhibitor 5-Aza-4′-thio-2′-Deoxycytidine Induces C>G Transversions and Acute Lymphoid Leukemia Development
Supp_Tables_S1-S13 from The DNA Methyltransferase Inhibitor 5-Aza-4′-thio-2′-Deoxycytidine Induces C>G Transversions and Acute Lymphoid Leukemia Development Open
Supp_Tables_S1-S13
View article: Supp_Tables_S1-S13 from The DNA Methyltransferase Inhibitor 5-Aza-4′-thio-2′-Deoxycytidine Induces C>G Transversions and Acute Lymphoid Leukemia Development
Supp_Tables_S1-S13 from The DNA Methyltransferase Inhibitor 5-Aza-4′-thio-2′-Deoxycytidine Induces C>G Transversions and Acute Lymphoid Leukemia Development Open
Supp_Tables_S1-S13
View article: Data from The DNA Methyltransferase Inhibitor 5-Aza-4′-thio-2′-Deoxycytidine Induces C>G Transversions and Acute Lymphoid Leukemia Development
Data from The DNA Methyltransferase Inhibitor 5-Aza-4′-thio-2′-Deoxycytidine Induces C>G Transversions and Acute Lymphoid Leukemia Development Open
DNA methyltransferase inhibitors (DNMTi), most commonly cytidine analogs, are compounds that decrease 5′-cytosine methylation. DNMTi are used clinically based on the hypothesis that cytosine demethylation will lead to re-expression of tumo…
View article: Supp_Fig_S1-S19 from The DNA Methyltransferase Inhibitor 5-Aza-4′-thio-2′-Deoxycytidine Induces C>G Transversions and Acute Lymphoid Leukemia Development
Supp_Fig_S1-S19 from The DNA Methyltransferase Inhibitor 5-Aza-4′-thio-2′-Deoxycytidine Induces C>G Transversions and Acute Lymphoid Leukemia Development Open
Supp_Fig_S1-S19
View article: Data from The DNA Methyltransferase Inhibitor 5-Aza-4′-thio-2′-Deoxycytidine Induces C>G Transversions and Acute Lymphoid Leukemia Development
Data from The DNA Methyltransferase Inhibitor 5-Aza-4′-thio-2′-Deoxycytidine Induces C>G Transversions and Acute Lymphoid Leukemia Development Open
DNA methyltransferase inhibitors (DNMTi), most commonly cytidine analogs, are compounds that decrease 5′-cytosine methylation. DNMTi are used clinically based on the hypothesis that cytosine demethylation will lead to re-expression of tumo…
View article: Supp_Fig_S1-S19 from The DNA Methyltransferase Inhibitor 5-Aza-4′-thio-2′-Deoxycytidine Induces C>G Transversions and Acute Lymphoid Leukemia Development
Supp_Fig_S1-S19 from The DNA Methyltransferase Inhibitor 5-Aza-4′-thio-2′-Deoxycytidine Induces C>G Transversions and Acute Lymphoid Leukemia Development Open
Supp_Fig_S1-S19
View article: The DNA Methyltransferase Inhibitor 5-Aza-4′-thio-2′-Deoxycytidine Induces C>G Transversions and Acute Lymphoid Leukemia Development
The DNA Methyltransferase Inhibitor 5-Aza-4′-thio-2′-Deoxycytidine Induces C>G Transversions and Acute Lymphoid Leukemia Development Open
DNA methyltransferase inhibitors (DNMTi), most commonly cytidine analogs, are compounds that decrease 5′-cytosine methylation. DNMTi are used clinically based on the hypothesis that cytosine demethylation will lead to re-expression of tumo…
View article: Sarcoma_CellminerCDB: A tool to interrogate the genomic and functional characteristics of a comprehensive collection of sarcoma cell lines
Sarcoma_CellminerCDB: A tool to interrogate the genomic and functional characteristics of a comprehensive collection of sarcoma cell lines Open
View article: 5-Aza-4’-thio-2’-deoxycytidine induces C>G transversions in a specific trinucleotide context and leads to acute lymphoid leukemia
5-Aza-4’-thio-2’-deoxycytidine induces C>G transversions in a specific trinucleotide context and leads to acute lymphoid leukemia Open
DNA methyltransferase inhibitors (DNMTi), most commonly cytidine analogs, are compounds that are used clinically to decrease 5’-cytosine methylation, with the aim of re-expression of tumor suppressor genes. We used a murine pre-clinical mo…
View article: Transcriptional profiling of canine osteosarcoma identifies prognostic gene expression signatures with translational value for humans
Transcriptional profiling of canine osteosarcoma identifies prognostic gene expression signatures with translational value for humans Open
Canine osteosarcoma is increasingly recognized as an informative model for human osteosarcoma. Here we show in one of the largest clinically annotated canine osteosarcoma transcriptional datasets that two previously reported, as well as de…
View article: The Role of FAS Receptor Methylation in Osteosarcoma Metastasis
The Role of FAS Receptor Methylation in Osteosarcoma Metastasis Open
Osteosarcoma is the most frequent primary malignant bone tumor with an annual incidence of about 400 cases in the United States. Osteosarcoma primarily metastasizes to the lungs, where FAS ligand (FASL) is constitutively expressed. The int…
View article: Targeting neddylation sensitizes colorectal cancer to topoisomerase I inhibitors by inactivating the DCAF13-CRL4 ubiquitin ligase complex
Targeting neddylation sensitizes colorectal cancer to topoisomerase I inhibitors by inactivating the DCAF13-CRL4 ubiquitin ligase complex Open
View article: NUP98::Nsd1 and FLT3-ITD collaborate to generate acute myeloid leukemia
NUP98::Nsd1 and FLT3-ITD collaborate to generate acute myeloid leukemia Open
View article: Data from Targeting Notch1 and IKKα Enhanced NF-κB Activation in CD133<sup>+</sup> Skin Cancer Stem Cells
Data from Targeting Notch1 and IKKα Enhanced NF-κB Activation in CD133<sup>+</sup> Skin Cancer Stem Cells Open
Cancer stem–like cells are hypothesized to be the major tumor-initiating cell population of human cutaneous squamous cell carcinoma (cSCC), but the landscape of molecular alterations underpinning their signaling and cellular phenotypes as …
View article: Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma Open
Differentially methylated regions with at least five CpGs, and a mean difference of greater than 20% between day 14 and baseline white blood cells
View article: Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma Open
Differentially methylated regions with at least five CpGs, and a mean difference of greater than 20% between day 14 and baseline white blood cells
View article: Supplementary Appendix S1 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
Supplementary Appendix S1 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma Open
Supplemental methods and figures
View article: Supplementary Appendix S1 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
Supplementary Appendix S1 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma Open
Supplemental methods and figures
View article: Data from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
Data from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma Open
Purpose:Succinate dehydrogenase (dSDH)-deficient tumors, including pheochromocytoma/paraganglioma, hereditary leiomyomatosis and renal cell cancer–associated renal cell carcinoma (HLRCC-RCC), and gastrointestinal stromal tumors (GIST) with…
View article: Data from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
Data from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma Open
Purpose:Succinate dehydrogenase (dSDH)-deficient tumors, including pheochromocytoma/paraganglioma, hereditary leiomyomatosis and renal cell cancer–associated renal cell carcinoma (HLRCC-RCC), and gastrointestinal stromal tumors (GIST) with…
View article: Data from Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model
Data from Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model Open
Purpose: New therapeutic approaches are needed for patients with thyroid cancer refractory to radioiodine treatment. An inhibitor of bromodomain and extraterminal domain (BET) proteins, JQ1, shows potent antitumor effects in hematol…
View article: Supplementary Figure Legend for Figure 2 from Assessment of Automated Image Analysis of Breast Cancer Tissue Microarrays for Epidemiologic Studies
Supplementary Figure Legend for Figure 2 from Assessment of Automated Image Analysis of Breast Cancer Tissue Microarrays for Epidemiologic Studies Open
Supplementary Figure Legend for Figure 2 from Assessment of Automated Image Analysis of Breast Cancer Tissue Microarrays for Epidemiologic Studies
View article: Supplementary Data from M<sup>6</sup>A RNA Methylation Regulates Histone Ubiquitination to Support Cancer Growth and Progression
Supplementary Data from M<sup>6</sup>A RNA Methylation Regulates Histone Ubiquitination to Support Cancer Growth and Progression Open
Supplementary Data from M6A RNA Methylation Regulates Histone Ubiquitination to Support Cancer Growth and Progression
View article: Supplementary Figure 1 from Assessment of Automated Image Analysis of Breast Cancer Tissue Microarrays for Epidemiologic Studies
Supplementary Figure 1 from Assessment of Automated Image Analysis of Breast Cancer Tissue Microarrays for Epidemiologic Studies Open
Supplementary Figure 1 from Assessment of Automated Image Analysis of Breast Cancer Tissue Microarrays for Epidemiologic Studies
View article: Data from M<sup>6</sup>A RNA Methylation Regulates Histone Ubiquitination to Support Cancer Growth and Progression
Data from M<sup>6</sup>A RNA Methylation Regulates Histone Ubiquitination to Support Cancer Growth and Progression Open
Osteosarcoma is the most common malignancy of the bone, yet the survival for patients with osteosarcoma is virtually unchanged over the past 30 years. This is principally because development of new therapies is hampered by a lack of recurr…